Physician profile
Chad P Bouchard
NPI 1831328053
$1,459.23
in general payments reported to CMS, 2019-2025
11 companies · $176 in 2025
The $176 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $60.90 · 2022: $442 · 2023: $460 · 2024: $321 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $957.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $956.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $472.16 | 2021-2025 | Vabysmo, Susvimo, Lucentis |
| Eyepoint US, INC. | $171.72 | 2022-2023 | |
| Abbvie INC. | $169.03 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $140.23 | 2023-2024 | Eylea, Eylea Hd |
| Genentech, INC. | $132.60 | 2022 | |
| Alimera Sciences, INC. | $97.14 | 2021-2024 | Yutiq, Iluvien |
| Apellis Pharmaceuticals, INC. | $96.05 | 2023-2025 | Syfovre |
| Astellas Pharma US INC | $69.72 | 2024-2025 | Izervay |
| Coherus Oncology, INC. | $65.23 | 2023-2024 | |
| Alcon Vision LLC | $26.50 | 2021 | |
| Ani Pharmaceuticals, INC. | $18.85 | 2025 | Iluvien |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Bouchard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.